Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trolamine polypeptide oleate condensate is a protein-based cerumenolytic agent that was marketed under the brand name Cerumenex for the removal of impacted earwax (cerumen). Formulated as a 10% otic solution, it functions as a surfactant that emulsifies and disperses earwax by lysing its components, thereby facilitating removal through water irrigation. The drug was initially developed by PRA Health Sciences and manufactured by The Purdue Frederick Company. It has since been withdrawn from the market, primarily due to concerns regarding potential ototoxicity in patients with a perforated tympanic membrane.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trolamine polypeptide oleate condensate.